Latest news

• Novartis adds oral eczema drug with Ziarco acquisition

  ZPL389 complements Novartis' existing dermatology medicines, which include Xolair (omalizumab) for chronic idiopathic urticaria (CIU) and recent launch Cosentyx (secukinumab) for psoriasis, as well as pipeline projects including atopic dermatitis

• AZ, BMS and Boehringer among UK Prix Galien finalists

  Pompe Disease. azacitidine. Vidaza. Celgene. Myslodysplastic Syndrome. omalizumab. Xolair. Novartis. Sever persistent allergic asthma.

• Mylan buys into six biosimilars, including Orencia candidate

  Prolia/Xgeva (denosumab) and Vectibix (panitumumab), Novartis' Xolair (omalizumab) and Sanofi's Campath (alemtuzumab), according to Evercore ISI analyst Umer Raffat.

• GSK bags FDA approval for severe asthma drug Nucala

  Roche and Novartis already sell a biologic drug for severe asthma - Xolair (omalizumab) - although this is approved for a different form of allergic asthma in which immunoglobulin E activation is a

• Teva set for FDA verdict on reslizumab early next year

  Novartis already sells a biologic drug for severe asthma - Xolair (omalizumab) - although this is approved for a different form of allergic asthma in which immunoglobulin E activation is a key driver